Skip to main content
SpringerLink
Log in

Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 2014; 71: 141–50.

    Article  CAS  Google Scholar 

  2. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17 receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181–9.

    Article  CAS  Google Scholar 

  3. Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol 2019; 181: 604–6.

    Article  CAS  Google Scholar 

  4. Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther 2020; 20: 665–72.

    Article  CAS  Google Scholar 

  5. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014; 71: 1183–90e3.

    Article  CAS  Google Scholar 

  6. Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Invest 2017; 37: 439–51.

    Article  CAS  Google Scholar 

  7. Umezawa Y, Nakagawa H, Niiro H, Ootaki K. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2016; 30: 1957–60.

    Article  CAS  Google Scholar 

  8. Regnault MM, Konstantinou M-P, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol 2017; 31: 1491–6.

    Article  Google Scholar 

  9. Khemis A, Cavalié M, Montaudié H, Lacour J-P, Passeron T. Rebound pustular psoriasis after brodalumab discontinuation. Br J Dermatol 2016; 175: 1065–6.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally

Authors and Affiliations

  1. Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France

    Marie Danset, Florence Hacard, Coline Jaulent, Audrey Nosbaum, Frédéric Berard, Jean-François Nicolas & Catherine Goujon

  2. CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5308, 21 Avenue Tony Garnier, 69007, Lyon, France

    Florence Hacard, Coline Jaulent, Audrey Nosbaum, Frédéric Berard & Jean-François Nicolas

Authors
  1. Marie Danset
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florence Hacard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Coline Jaulent
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Audrey Nosbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frédéric Berard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-François Nicolas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Catherine Goujon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Marie Danset or Catherine Goujon.

Additional information

Disclosures

Conflicts of interest: Catherine Goujon has received funds from the following: Abbvie, Celgene, Janssen Cilag, Leo, Lilly, Novartis, Pfizer. None of the other authors have any conflicts of interest to declare.

Supplementary material

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Danset, M., Hacard, F., Jaulent, C. et al. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal. Eur J Dermatol 30, 741–743 (2020). https://doi.org/10.1684/ejd.2020.3910

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2020.3910

Search

Navigation